Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Inozyme Pharma Inc INZY

Healthcare Biotechnology
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:INZY)

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

GlobeNewswire 8 days ago

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 10 days ago

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 2, 2024

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

GlobeNewswire March 26, 2024

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

GlobeNewswire March 12, 2024

Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 26, 2024

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 6, 2024

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 5, 2023

Inozyme Pharma to Participate in Upcoming Investor Conferences

GlobeNewswire November 9, 2023
View More News ››

Opinion & Analysis (NDAQ:INZY)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:INZY)

$INZY reports strong financial results and CEO succession

https://stcred.com/nasdaq-inzy/announcement-inzy-8-k-special-filing/sP037u
streetcred - March 22, 2023

INZY ...early a.m runner on Positive NR

$3.15....No position
Iseneschal - February 16, 2023
View more Bullboard ››

Interactive Capital Partners Corporation

Interactive Capital Partners Corporation

View More »